Groupama Asset Managment boosted its position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 30.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 86,725 shares of the company's stock after acquiring an additional 19,994 shares during the period. Groupama Asset Managment's holdings in BioNTech were worth $9,764,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Daiwa Securities Group Inc. boosted its stake in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock worth $221,000 after acquiring an additional 128 shares during the period. Bank of New York Mellon Corp boosted its position in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after acquiring an additional 150 shares during the last quarter. Midwest Professional Planners LTD. grew its stake in BioNTech by 5.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after acquiring an additional 222 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in BioNTech by 3.9% in the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock worth $666,000 after purchasing an additional 224 shares in the last quarter. Finally, Atomi Financial Group Inc. boosted its holdings in shares of BioNTech by 6.7% during the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock valued at $414,000 after purchasing an additional 229 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.
Analyst Upgrades and Downgrades
BNTX has been the topic of a number of research analyst reports. Truist Financial initiated coverage on BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 target price on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 target price on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup started coverage on shares of BioNTech in a research report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target on the stock. Morgan Stanley dropped their price objective on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright decreased their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $143.44.
Get Our Latest Research Report on BioNTech
BioNTech Stock Down 4.3 %
BioNTech stock traded down $3.96 during midday trading on Friday, hitting $88.05. 1,035,719 shares of the company's stock were exchanged, compared to its average volume of 841,431. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The firm has a 50-day moving average of $108.81 and a two-hundred day moving average of $112.88. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a market cap of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07.
BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.90 earnings per share. As a group, analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.
About BioNTech
(
Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Read More
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
